Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Two Healthcare-Focused Funds Buy More Shares Of 2 Promising Companies, While Activist Cashes Out Of IT Company

You don’t necessarily need millions of dollars to invest like an activist investor such as Carl Icahn or Bill Ackman. Extensive research has concluded that activist targets tend to greatly outperform stock market benchmarks, which is one of the primary reasons that a high number of individual investors track activist campaigns. Activist investors piling up more than 5% of a company’s outstanding common stock and planning to push for changes at the company in question must submit a Schedule 13D filing with the SEC within ten days following the acquisition of those shares. With that in mind, the following article will examine and discuss three 13D forms filed by several hedge funds monitored by Insider Monkey.

Let’s first take a step back and analyze how tracking hedge funds can help an everyday investor. Through our research we discovered that a portfolio of the 15 most popular small-cap picks of hedge funds beat the S&P 500 Total Return Index by nearly a percentage point per month on average between 1999 and 2012. On the other hand the most popular large-cap picks of hedge funds underperformed the same index by seven basis points per month during the same period. This is likely a surprise to many investors, who think of small-caps as risky, unpredictable stocks and put more faith (and money) in large-cap stocks. In forward tests since August 2012 these top small-cap stocks beat the market by an impressive 53 percentage points, returning 102% (read the details here). Follow the smart money into only their best investment ideas all while avoiding their high fees.

In a freshly-amended 13D filing with the SEC, Samuel Isaly’s Orbimed Advisors reported owning 1.70 million shares of Ascendis Pharma A/S (NASDAQ:ASND), accounting for 6.78% of the company’s outstanding stock. This compares with the 1.45 million-share position revealed in its first (and latest) 13D filing on the biopharmaceutical company, which was submitted with the SEC at the beginning of the year. The clinical-stage biotechnology company that utilizes its TransCon technology to develop products that treat unmet medical needs has seen its stock decline by 10% since its initial public offering that took place at the end of January. Ascendis Pharma A/S (NASDAQ:ASND) raised $108 million by offering to the public 6.0 million shares at an IPO price of $18. The company’s lead product candidate, TransCon hGH, aims to treat growth hormone deficiency, and is believed to have great potential should it get approved. Ascendis plans to initiate a Pivotal Phase III trial in pediatric growth hormone deficient patients in mid-2016. The worldwide sales from the currently commercialized hGH products climbed to over $3 billion in 2013, according to Medtrack.

Samuel Isaly
Samuel Isaly
OrbiMed Advisors

Nevertheless, the biotech stock lost its charm within the hedge fund industry in the third quarter, as the number of smart money investors with positions in the company decreased to 13 from 19. The value of their investments dropped to $91.22 million from $109.74 million quarter-over-quarter, while the stock was flat during that time. At the same time, these hedge fund firms held slightly more than 21% of the company’s shares on September 30. Peter Kolchinsky’s RA Capital Management cut its position in Ascendis Pharma A/S (NASDAQ:ASND) by 451,885 shares during the third quarter to 1.46 million shares.

Let’s head to the next page of the article, where we discuss the recently-made moves of activist JANA Parners and healthcare-focused Baker Bros. Advisors.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.